Shinobi Therapeutics, a San Francisco, CA-based biotechnology company developing a new class of immune evasive iPS cell therapies, received a $59M grant.
The non-dilutive grant funding, provided by the Japanese Agency for Medical Research and Development (AMED), will support the development of the company’s lead program, an iPS-T cell therapy targeting GPC3+ solid tumor cancers.
Shinobi also announced an extension of its Series A round, bringing the company’s total funding to $119M, with the addition of Yosemite and Mitsubishi UFJ Capital as investors.
Led by CEO Dan Kemp, Shinobi Therapeutics is a biotechnology company developing a new class of off-the-shelf immune evasive iPSC-derived cell therapies. Shinobi’s immune evasive iPS-T cell technology, built upon a decade of research by scientific co-founders Tobias Deuse, M.D. and Shin Kaneko, M.D., Ph.D., enables a new class of off-the-shelf cell therapies that work with, not against, the patient’s immune system.
The company has also recently cemented partnerships with Panasonic around scaled manufacturing and Anocca for TCR discovery and development.
